High adherence to the 'Wise List' treatment recommendations in Stockholm: A 15-year retrospective review of a multifaceted approach promoting rational use of medicines

BMJ Open

Volumn 7, Issue 4, 2017, Pages

  Eriksen, Jaran ^a,b   Gustafsson, Lars L ^a,b   Ateva, Kristina ^c   Bastholm Rahmner, Pia ^a   Ovesjö, Marie Louise ^a,d   Jirlow, Malena ^c   Juhasz Haverinen, Maria ^c   Lärfars, Gerd ^a   Malmström, Rickard E ^a   Wettermark, Björn ^a   Andersén Karlsson, Eva ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Public Healthcare Services Committee Administration   (Sweden)

^d STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Adherence; Drug and therapeutics committee; Essential medicines; Health systems; prescribing; Rational Use of Medicines

Indexed keywords

ALTERNATIVE MEDICINE; CONFLICT OF INTEREST; FEMALE; HOSPITAL; HUMAN; HUMAN EXPERIMENT; MALE; MEDICAL EDUCATION; PRESCRIPTION; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; AMBULATORY CARE; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; DRUG UTILIZATION; EVIDENCE BASED PRACTICE; PHARMACY AND THERAPEUTICS COMMITTEE; PRACTICE GUIDELINE; PROTOCOL COMPLIANCE; STANDARDS; STATISTICS AND NUMERICAL DATA; SWEDEN;

ESSENTIAL DRUG;

AMBULATORY CARE; COST-BENEFIT ANALYSIS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; DRUGS, ESSENTIAL; EVIDENCE-BASED PRACTICE; GUIDELINE ADHERENCE; HUMANS; PHARMACY AND THERAPEUTICS COMMITTEE; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; RETROSPECTIVE STUDIES; SWEDEN;

EID: 85018727541     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-014345     Document Type: Review

References (48)

1. Bergman U, Wiholm BE. Drug-related problems causing admission to a medical clinic. Eur J Clin Pharmacol 1981;20:193-200.
2. Davies EC, Green CF, Taylor S, et al. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE 2009;4:e4439.
3. Mölstad S, Erntell M, Hanberger H, et al. Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. Lancet Infect Dis 2008;8:125-32.
4. WHO. The rational use of drugs - report of the conference of experts Nairobi, 25-29 November 1985. Geneva, Switzerland: World Health Organization, 1987. http://appswhoint/medicinedocs/documents/s17054e/s17054epdf
5. McGinn D, Godman B, Lonsdale J, et al. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev Pharmacoecon Outcomes Res 2010;10:73-85.
6. Norman C, Zarrinkoub R, Hasselström J, et al. Potential savings without compromising the quality of care. Int J Clin Pract 2009;63:1320-6.
7. Fijn R, Brouwers JR, Knaap RJ, et al. Drug and Therapeutics (D & T) committees in Dutch hospitals: a nation-wide survey of structure, activities, and drug selection procedures. Br J Clin Pharmacol 1999;48:239-46.
8. Sjöqvist F, Bergman U, Dahl M, et al. Drug and therapeutics committees: a Swedish experience. WHO Drug Information 2002;16:207.
9. Birkett D, Brøsen K, Cascorbi I, et al. Clinical pharmacology in research, teaching and health care: considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol 2010;107:531-59.
10. WHO. The Selection of Essential Drugs: Report of a WHO Expert Committee. Technical Report Series no 615. Geneva, Switzerland: World Health Organization, 1977.
11. Schiff GD, Galanter WL, Duhig J, et al. A prescription for improving drug formulary decision making. PLoS Med 2012;9:1-7.
12. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet 2003;362:1225-30.
13. Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care 2001;39(8 Suppl 2):II46-54.
14. Godman B, Wettermark B, Hoffmann M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res 2009;9:65-83.
15. Gustafsson LL, Wettermark B, Godman B, et al. The 'wise list' - a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011;108:224-33.
16. Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004;8:iii-iv, 1-72.
17. Grol R, Dalhuijsen J, Thomas S, et al. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. BMJ 1998;317:858-61.
18. Bjorkhem-Bergman L, Andersen-Karlsson E, Laing R, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol 2013;69(Suppl 1):73-8.
19. Wettermark B, Haglund K, Gustafsson LL, et al. A study of adherence to drug recommendations by providing feedback of outpatient prescribing patterns to hospital specialists. Pharmacoepidemiol Drug Saf 2005;14:579-88.
20. The Stockholm Drug and Therapeutics Committee. The Wise List 2015 in English. Stockholm, Sweden: Stockholm Healthcare Region, 2015. http://wwwjanusinfose/In-English/The-Wise-List-2015-in-English/.
21. Kumar Kakkar A, Dahiya N. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space. Drug Dev Res 2014;75:231-4.
22. Yeh JS, Franklin JM, Avorn J, et al. Association of industry payments to physicians with the prescribing of brand-name Statins in Massachusetts. JAMA Intern Med 2016;176:763-8.
23. Lieb K, Scheurich A. Contact between doctors and the pharmaceutical industry, their perceptions, and the effects on prescribing habits. PLoS ONE 2014;9:e110130.
24. Abbasi K, Smith R. No more free lunches. BMJ 2003;326:1155-6.
25. Stockholm County Counsil DTC. Jävspolicy för läkemedelskommittéorganisationen i Stockholms läns landsting (SLL). 2011. http://www.janusinfo.se/Global/SLK/javspolicy-slk- 2011-2.pdf2016.
26. WHO. WHO model list of essential medicines - 19th list. Geneva, Switzerland: World Health Organization, 2015. http://www.who.int/medicines/publications/essentialmedicines/en/
27. Anell A. The public-private pendulum - patient choice and equity in Sweden. N Engl J Med 2015;372:1-4.
28. WHO. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment, 2015. Oslo: World Health Organization, 2014.
29. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register - opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-35.
30. Vlahović-Palcevski V, Gantumur M, Radosević N, et al. Coping with changes in the defined daily dose in a longitudinal drug consumption database. Pharm World Sci 2010;32:125-9.
31. Andersson K, Bergström G, Petzold MG, et al. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals. Health Policy 2007;81:376-84.
32. Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res 2010;10:707-22.
33. Godman B, Malmstrom RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol 2015;8:77-94.
34. Bergman U, Popa C, Tomson Y, et al. Drug utilization 90% - a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol 1998;54:113-18.
35. Wettermark B, Pehrsson A, Juhasz-Haverinen M, et al. Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care. Qual Prim Care 2009;17:179-89.
36. Hjemdahl P, Allhammar A, Heaton C, et al. [SBU should investigate what is an evidence-based and cost-effective use of statins]. Lakartidningen 2009;106:1992-4.
37. Gellad WF, Choi P, Mizah M, et al. Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011. Am J Manag Care 2014;20:e90-7.
38. Fosbøl EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010;3:395-405.
39. Swedish Medical Products Agency. National Substance Register for Medicinal Products (NSL). 2016. http://nsl.mpa.se/index-english. htm2016
40. Stammen LA, Stalmeijer RE, Paternotte E, et al. Training physicians to provide high-value, cost-conscious care: a systematic review. JAMA 2015;314:2384-400.
41. Dreischulte T, Donnan P, Grant A, et al. Safer prescribing - a trial of education, informatics, and financial incentives. N Engl J Med 2016;374:1053-64.
42. Oxman AD, Thomson MA, Davis DA, et al. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. CMAJ 1995;153:1423-31.
43. Wolfe S. Rosuvastatin: winner in the statin wars, patients' health notwithstanding. BMJ 2015;350:h1388.
44. Lapointe-Shaw L, Fischer HD, Newman A, et al. Potential savings of harmonising hospital and community formularies for chronic disease medications initiated in hospital. PLoS ONE 2012;7:e39737.
45. Donohue JM, Morden NE, Gellad WF, et al. Sources of regional variation in Medicare Part D drug spending. N Engl J Med 2012;366:530-8.
46. Wettermark B, Persson ME, Wilking N, et al. Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv Res 2010;10:128.
47. Wirtz VJ, Hogerzeil HV, Gray AL, et al. Essential medicines for universal health coverage. Lancet 2017;389:403-76.
48. Komen J, Forslund T, Hjemdahl P, et al. Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. Br J Clin Pharmacol 2017;83:642-52.